218 related articles for article (PubMed ID: 32738490)
21. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Tekwani BL
N Engl J Med; 2020 Sep; 383(11):1088-1089. PubMed ID: 32668108
[No Abstract] [Full Text] [Related]
22. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19.
Khan MS; Butler J
N Engl J Med; 2020 Sep; 383(11):1088. PubMed ID: 32668107
[No Abstract] [Full Text] [Related]
23. Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. Reply.
Okafor EC; Pastick KA; Rajasingham R
N Engl J Med; 2020 Sep; 383(11):1089. PubMed ID: 32668109
[No Abstract] [Full Text] [Related]
24. Review of: "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial Gautret et al 2010, DOI:10.1016/j.ijantimicag.2020.105949.
Rosendaal FR
Int J Antimicrob Agents; 2020 Jul; 56(1):106063. PubMed ID: 32674928
[No Abstract] [Full Text] [Related]
25. Conflicting evidence on the efficacy of hydroxychloroquine and azithromycin as the early treatment of COVID-19. Comment on "Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France".
Bonny A; Talle MA; Ngantcha M; Tayebjee MH
Travel Med Infect Dis; 2020; 37():101861. PubMed ID: 32889105
[No Abstract] [Full Text] [Related]
26. Recent Findings on Cardiovascular Safety With the Use of Chloroquine and Hydroxychloroquine for COVID-19.
Guzman-Prado Y
Am J Cardiol; 2020 Sep; 130():162-163. PubMed ID: 32624192
[No Abstract] [Full Text] [Related]
27. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
Palmeira VA; Costa LB; Perez LG; Ribeiro VT; Lanza K; Silva ACSE
Clinics (Sao Paulo); 2020; 75():e1928. PubMed ID: 32401962
[No Abstract] [Full Text] [Related]
28. Hydroxychloroquine, Coronavirus Disease 2019, and QT Prolongation.
Bonow RO; Hernandez AF; Turakhia M
JAMA Cardiol; 2020 Sep; 5(9):986-987. PubMed ID: 32936259
[No Abstract] [Full Text] [Related]
29. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.
R Karim HM; Ahmed G
Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):119-120. PubMed ID: 32773410
[No Abstract] [Full Text] [Related]
30. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
Tilangi P; Desai D; Khan A; Soneja M
Lancet Infect Dis; 2020 Oct; 20(10):1119-1120. PubMed ID: 32450054
[No Abstract] [Full Text] [Related]
31. Chloroquine or hydroxychloroquine for prophylaxis of COVID-19.
Principi N; Esposito S
Lancet Infect Dis; 2020 Oct; 20(10):1118. PubMed ID: 32311322
[No Abstract] [Full Text] [Related]
32. A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19.
Kim AHJ; Sparks JA; Liew JW; Putman MS; Berenbaum F; Duarte-García A; Graef ER; Korsten P; Sattui SE; Sirotich E; Ugarte-Gil MF; Webb K; Grainger R;
Ann Intern Med; 2020 Jun; 172(12):819-821. PubMed ID: 32227189
[TBL] [Abstract][Full Text] [Related]
33. [Not Available].
Farfán-López M; Espinoza-Culupú A
Rev Peru Med Exp Salud Publica; 2020; 37(2):383-384. PubMed ID: 32876237
[No Abstract] [Full Text] [Related]
34. Chloroquine and Hydroxychloroquine in COVID-19: Challenges and the Need for Caution in Low-Resource Settings.
Islam M
J Coll Physicians Surg Pak; 2020 Jun; 30(6):78. PubMed ID: 32723461
[No Abstract] [Full Text] [Related]
35. An Ounce of Prevention and a Pound of Cure: Randomized Clinical Trials of Therapeutics Against COVID-19 and an Assessment of Personal Protective Equipment and Distancing.
Sher DJ
Int J Radiat Oncol Biol Phys; 2020 Oct; 108(2):333-336. PubMed ID: 32890500
[No Abstract] [Full Text] [Related]
36. RE: "EARLY OUTPATIENT TREATMENT OF SYMPTOMATIC, HIGH-RISK COVID-19 PATIENTS THAT SHOULD BE RAMPED UP IMMEDIATELY AS KEY TO THE PANDEMIC CRISIS".
Peiffer-Smadja N; Costagliola D
Am J Epidemiol; 2020 Nov; 189(11):1443-1444. PubMed ID: 32685975
[No Abstract] [Full Text] [Related]
37. Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine.
Sahraei Z; Shabani M; Shokouhi S; Saffaei A
Int J Antimicrob Agents; 2020 Apr; 55(4):105945. PubMed ID: 32194152
[No Abstract] [Full Text] [Related]
38. Chloroquine and hydroxychloroquine for COVID-19: implications for cardiac safety.
Jeevaratnam K
Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):256-257. PubMed ID: 32347923
[No Abstract] [Full Text] [Related]
39. Re: Chloroquine (CQ) and Hydroxychloroquine (HQ) Retinal Toxicity Consideration in the Treatment of the Coronavirus Disease 2019 (COVID-19).
Ruamviboonsuk P; Lai TYY; Chang A; Lai CC; Mieler WF; Lam DSC
Asia Pac J Ophthalmol (Phila); 2020; 9(4):375-376. PubMed ID: 32740072
[No Abstract] [Full Text] [Related]
40. Chloroquine, Hydroxychloroquine, Retinal Toxicity, and COVID-19.
Wiwanitkit V
Asia Pac J Ophthalmol (Phila); 2020; 9(4):374. PubMed ID: 32740070
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
